{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:09:56Z","timestamp":1773659396110,"version":"3.50.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.drudis.2014.02.011","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T17:47:18Z","timestamp":1394214438000},"page":"921-935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Latest developments in anticoagulant drug discovery"],"prefix":"10.1016","volume":"19","author":[{"given":"Erasmia","family":"Broussalis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wallner","family":"Anna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Mutzenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Killer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2014.02.011_bib0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/2040620712453067","article-title":"Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism","volume":"3","author":"Turpie","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0010","first-page":"442","article-title":"Antithrombotic therapy in atrial fibrillation and additional stroke\/embolism risk factors. CORSurvey Study","volume":"88","author":"Stollberger","year":"1999","journal-title":"Z. Kardiol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1755-5922.2010.00197.x","article-title":"Alternatives to warfarin \u2013 the next generation of anticoagulants","volume":"29","author":"Kanagasabapathy","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.drudis.2014.02.011_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/pgs.11.184","article-title":"Prediction of warfarin dose: why, when and how?","volume":"13","author":"Eriksson","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2014.02.011_bib0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/europace\/eur263","article-title":"Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents","volume":"14","author":"Bassand","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.drudis.2014.02.011_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0037-1616898","article-title":"New anticoagulants: from bench to bedside","volume":"27","author":"Haas","year":"2007","journal-title":"Haemostaseologie"},{"key":"10.1016\/j.drudis.2014.02.011_bib0035","first-page":"39","article-title":"The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?","volume":"54","author":"Prandoni","year":"2012","journal-title":"Panminerva Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0040","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2014.02.011_bib0045","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2014.02.011_bib0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.02.011_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Committee","year":"2009","journal-title":"J. Arthroplasty"},{"key":"10.1016\/j.drudis.2014.02.011_bib0060","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-Model randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (Re-novate II*). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0070","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0080","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review","volume":"157","author":"Adam","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0085","first-page":"433","article-title":"Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs","volume":"13","author":"Ahrens","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0090","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMe0906886","article-title":"Can we rely on RE-LY?","volume":"361","author":"Gage","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0095","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040622312438934","article-title":"Novel anticoagulants in atrial fibrillation stroke prevention","volume":"3","author":"Norgard","year":"2012","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.drudis.2014.02.011_bib0105","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options \u2013 why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0110","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0115","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.02.011_bib0120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurjhf\/hfp102","article-title":"Clinical trials update from the european society of cardiology heart failure meeting 2009: Chance, B-Convinced, Chat Cibis-ELD, and Signal-HF","volume":"11","author":"Cleland","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.drudis.2014.02.011_bib0125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000342307","article-title":"Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report","volume":"34","author":"Marrone","year":"2012","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.drudis.2014.02.011_bib0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000319886","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran","volume":"30","author":"De Smedt","year":"2010","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.drudis.2014.02.011_bib0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drudis.2014.02.011_bib0140","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","article-title":"Drug and dietary interactions of the new and emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.drudis.2014.02.011_bib0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pharmthera.2010.09.005","article-title":"Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data","volume":"129","author":"Ma","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2014.02.011_bib0150","unstructured":"Dabigatran medication guide. Available at: http:\/\/bidocs.boehringeringelheim.com\/BIWebAccess\/ViewServlet.ser?docBase\u00bcrenetnt&-folderPath\u00bc\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf"},{"key":"10.1016\/j.drudis.2014.02.011_bib0155","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0160","article-title":"No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract]","volume":"5","author":"Stangier","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2014.02.011_bib0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0175","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.02.011_bib0180","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.02.011_bib0190","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Einstein-PE Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0195","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Einstein-PE Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/fca.12.26","article-title":"Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome","volume":"8","author":"Ahrens","year":"2012","journal-title":"Future Cardiol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0205","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0220","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1517\/13543784.17.6.925","article-title":"Rivaroxaban, an oral direct factor xa inhibitor","volume":"17","author":"Piccini","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2014.02.011_bib0225","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939) \u2013 an oral, direct factor Xa inhibitor \u2013 has no clinically relevant interaction with naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0230","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban \u2013 an oral, direct factor Xa inhibitor \u2013 are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0235","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the h2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0240","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2014.02.011_bib0245","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0250","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (advance-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.02.011_bib0255","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0260","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","article-title":"Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from averroes, a randomised trial","volume":"11","author":"Diener","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0270","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1161\/STROKEAHA.112.664144","volume":"43","author":"Flaker","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2014.02.011_bib0275","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0280","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"Wallentin","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.02.011_bib0285","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0290","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1160\/TH10-12-0808","article-title":"What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?","volume":"105","author":"Ahrens","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0295","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome p450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2014.02.011_bib0300","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1124\/dmd.108.025981","article-title":"Comparative metabolism of 14c-labeled apixaban in mice, rats, rabbits, dogs, and humans","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2014.02.011_bib0305","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0310","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial","volume":"119","author":"Committee","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.02.011_bib0315","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0320","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0325","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/dmd.112.050260","article-title":"Characterization of efflux transporters involved in distribution and disposition of apixaban","volume":"41","author":"Zhang","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2014.02.011_bib0330","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2146\/ajhp110418","article-title":"Apixaban: a novel oral inhibitor of factor Xa","volume":"69","author":"Nutescu","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.drudis.2014.02.011_bib0335","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2014.02.011_bib0340","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2012-002218","article-title":"Direct treatment comparison of dabigatran and rivaroxaban versus nadroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)","volume":"3","author":"Veen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2014.02.011_bib0350","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1160\/TH12-05-0298","article-title":"Contra: \u2018Antidotes for novel anticoagulants?\u2019 \u2013 do we really need them","volume":"108","author":"Eerenberg","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"Suppl.","key":"10.1016\/j.drudis.2014.02.011_bib0355","first-page":"a573","article-title":"Evaluation of recombinant activated facror VII, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model (presented at the ACC 2012 meeting as an oral presentation)","volume":"59","author":"Martin","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH11-09-0668","article-title":"Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents","volume":"107","author":"Fukuda","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0365","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2014.02.011_bib0370","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/157340310791658749","article-title":"Antithrombotic therapy in cardiac embolism","volume":"6","author":"Cervera","year":"2010","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.drudis.2014.02.011_bib0375","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1631\/jzus.B1201007","article-title":"Clinical considerations of anticoagulation therapy for patients with atrial fibrillation","volume":"13","author":"Zhang","year":"2012","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.drudis.2014.02.011_bib0380","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (re-align)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0385","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0390","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"77","author":"Hori","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0395","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"Gibson","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0400","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/erc.09.37","article-title":"Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: The Record Trials","volume":"7","author":"Ageno","year":"2009","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.drudis.2014.02.011_bib0405","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0410","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0415","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"Du-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0420","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5482\/HAMO-12-05-0004","article-title":"Oral anticoagulation with edoxaban. Focus on current phase III clinical development","volume":"32","author":"Ahrens","year":"2012","journal-title":"Haemostaseologie"},{"key":"10.1016\/j.drudis.2014.02.011_bib0425","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH10-02-0142","article-title":"Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study","volume":"104","author":"Raskob","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0430","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0435","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","article-title":"Randomized, multicenter, warfarin-controlled phase II study of edoxaban in japanese patients with non-valvular atrial fibrillation","volume":"76","author":"Yamashita","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.02.011_bib0440","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2125.2011.04001.x","article-title":"Inhibitors of propagation of coagulation: factors V and X","volume":"72","author":"Toschi","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0445","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1160\/TH06-05-0234","article-title":"Emerging anticoagulants for the treatment of venous thromboembolism","volume":"96","author":"Weitz","year":"2006","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drudis.2014.02.011_bib0455","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0460","first-page":"445","article-title":"Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation","volume":"13","author":"Ahrens","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.drudis.2014.02.011_bib0465","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (EXPLORE-Xa)","volume":"34","author":"Connolly","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0470","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.10.009","article-title":"Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor","volume":"673","author":"Iwatsuki","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0475","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0480","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0485","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/ehm.10.5","article-title":"Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (factor Xa inhibitors)","volume":"3","author":"Mehta","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0490","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"Ruby-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0495","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/ATVBAHA.107.158691","article-title":"Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct factor Xa inhibitor, compared with antiplatelet agents in pigs","volume":"28","author":"McBane","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0500","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1160\/TH07-09-0576","article-title":"Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis","volume":"99","author":"Karnicki","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0505","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1160\/TH10-05-0273","article-title":"A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/157488412800958677","article-title":"Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?","volume":"7","author":"Deftereos","year":"2012","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.02.011_bib0515","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1634\/theoncologist.12-8-927","article-title":"Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein)","volume":"12","author":"Marchetti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2014.02.011_bib0520","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/13543784.2011.562190","article-title":"Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes","volume":"20","author":"Romualdi","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2014.02.011_bib0525","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0037-1617033","article-title":"Factor Xa inhibitors \u2013 new anticoagulants for secondary haemostasis","volume":"29","author":"Perzborn","year":"2009","journal-title":"Haemostaseologie"},{"key":"10.1016\/j.drudis.2014.02.011_bib0530","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0535","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2010.11.012","volume":"127","author":"Lip","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2014.02.011_bib0540","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehp318","article-title":"Oral direct thrombin inhibitor azd0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists","volume":"30","author":"Lip","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2014.02.011_bib0545","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1160\/TH09-07-0509","article-title":"Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation","volume":"103","author":"Olsson","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2011.08.018","article-title":"Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists","volume":"129","author":"Wolzt","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2014.02.011_bib0555","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Partial factor IXa inhibition with ttp889 for prevention of venous thromboembolism: an exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.02.011_bib0560","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J. Clin. Pharmacol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:17:59Z","timestamp":1761221879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644614000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":112,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1359644614000737"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2014.02.011","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latest developments in anticoagulant drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2014.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}